Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies

Synpsyure提供对专有抗体-药物偶联物（ADC）技术的访问

SOTIO to develop up to three next generation bioconjugates

SOTIO开发多达三种下一代生物共轭物

Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs

总潜在交易价值高达7.4亿美元，以及三个ADC项目的商业销售版税

AMSTERDAM, Oct. 16, 2023 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, enters licensing agreement with SOTIO Biotech (SOTIO), a clinical stage immuno-oncology company owned by PPF Group..

阿姆斯特丹，2023年10月16日/PRNewswire/-Synpexure B.V.，Lonza公司（SIX:LONN）专注于将其临床阶段平台技术商业化，用于开发具有一流治疗指数的抗体-药物偶联物（ADC），与PPF集团拥有的临床阶段免疫肿瘤公司SOTIO Biotech（SOTIO）签订许可协议。。

SOTIO will gain access to Synaffix's ADC technologies, GlycoConnect™, HydraSpace™ and toxSYN™ linker-payloads, in an initial ADC program with the option to expand research and commercial licenses into two additional programs at a later date.

SOTIO将获得Synpsyure的ADC技术GlycoConnect™, 水空间™ 和毒素™ 链接器有效载荷，在最初的ADC计划中，可以选择在以后将研究和商业许可扩展到另外两个计划。

Under the terms of the agreement, Synaffix will be eligible to receive up to $740 million in payments spanning signature, target nomination and milestone payments plus additional royalties on commercial sales. SOTIO will be responsible for the research, development, and commercialization of the ADCs.

根据协议条款，Synpathu将有资格获得高达7.4亿美元的跨越签名，目标提名和里程碑付款的付款以及商业销售的额外版税。SOTIO将负责ADC的研究，开发和商业化。

Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies..

Synpsyure将负责制造与其专有技术特别相关的组件。。

Peter van de Sande, Head of Synaffix, said: 'The selection of our ADC technologies by a seasoned ADC player like SOTIO is a strong recognition of the potential of these technologies to maximize the therapeutic index of ADCs. We look forward to partnering with SOTIO, and believe that with their singular focus on cancer immunotherapies and robust clinical pipeline, this partnership can deliver innovative medicines for patients in areas of high unmet medical need.' .

Synpsynux负责人Peter van de Sande说：“由SOTIO等经验丰富的ADC玩家选择我们的ADC技术，强烈认识到这些技术有可能最大限度地提高ADC的治疗指数。我们期待与SOTIO合作，并相信，凭借其专注于癌症免疫疗法和强大的临床渠道，这种合作关系可以为高度未满足医疗需求的患者提供创新药物 .

Radek Spisek, Chief Executive Officer of SOTIO, said: 'At SOTIO, we are building a broad pipeline of next-generation ADCs to address the challenges of solid tumors – and access to Synaffix's ADC platform technologies will ensure we remain at the leading edge of this space. This collaboration combining SOTIO's deep expertise in solid tumor drug development with Synaffix's clinical-stage platform technology will drive important new innovations for the benefit of patients.'.

SOTIO首席执行官Radek Spisek表示：“在SOTIO，我们正在建立一个广泛的下一代ADC管道，以应对实体瘤的挑战-使用Synpsyure的ADC平台技术将确保我们保持领先地位这个空间的边缘。这项合作将SOTIO在实体肿瘤药物开发方面的丰富专业知识与Synpexure的临床阶段平台技术相结合，将为患者带来重要的新创新。

Synaffix was fully acquired by Lonza in June 2023 and represents a newly formed 'Center of Excellence' for bioconjugation. As a Lonza company, Synaffix will continue to operate under the Synaffix name and further expand its operations in Oss (NL) to cater for further innovation and growth.

Synpsyque于2023年6月被Lonza完全收购，代表了新成立的生物共轭“卓越中心”。作为Lonza公司，Synplux将继续以Synplux名称运营，并进一步扩大其在Oss（NL）的运营，以满足进一步的创新和增长。

About Synaffix

关于语法

Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace™ and toxSYN™, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix..

Synpsynux B.V.是一家生物技术公司，可使用基于GlycoConnect的临床阶段，特定于站点的ADC技术平台为ADC产品候选人提供支持™, 水空间™ 和毒素™, 一起使任何拥有抗体的公司能够在Synpexure的单一许可下开发专有的一流ADC产品。。

The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix' technology provide end-to-end protection of the manufacturing technology as well as the resulting products through at least 2039. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen (acquired by Lepu Biopharma), Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics, Emergence Therapeutics (acquired by Eli Lilly), Amgen, Hummingbird Biosciences, Chong Kun Dang Pharma and ABL Bio..

由于已建立的技术组件供应链，Synpexure平台可实现快速的临床时间表。授予涵盖Synpsyque技术的专利至少在2039年之前为制造技术以及所得产品提供端到端保护。Synpsynux的商业模式是针对特定目标的技术许可证，例如其与ADC Therapeutics，Mersana Therapeutics，Shanghai Miracogen（由Lepu Biopharma收购），Innovent Biologics，ProfoundBio，Kyowa Kirin，Genmab，Macrogenics，Emergence Therapeutics的现有交易。（由礼来公司收购），安进公司，蜂鸟生物科学公司，冲坤当制药公司和ABL Bio。。

Synaffix was fully acquired by Lonza in June 2023.

Synpsyque于2023年6月被Lonza完全收购。

About The Synaffix ADC Platform Technology

关于Synpexure ADC平台技术

Synaffix' proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies.  These technologies are aimed at enabling best-in-class ADCs from any antibody, with significantly enhanced efficacy and tolerability.

Synpsyure专有的ADC技术平台由GlycoConnect组成™, 水空间™ 和毒素™ 技术。这些技术旨在使任何抗体的一流ADC具有显着增强的功效和耐受性。

GlycoConnect™ is a clinical-stage conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats. HydraSpace™ is a clinical-stage compact and highly polar spacer technology that is designed to further enhance therapeutic index, particularly with hydrophobic payloads.

GlycoConnect™ 是一种临床阶段结合技术，利用天然抗体聚糖进行位点特异性和稳定的有效载荷附着，可调节为DAR1，DAR2或DAR4形式。水空间™ 是一种临床阶段紧凑且高极性的间隔技术，旨在进一步提高治疗指数，特别是疏水有效载荷。

toxSYN™ is a linker-payload platform that spans key, validated MOAs for ADC product development. This includes potent topoisomerase 1 inhibitor (SYNtecan E™), DNA damaging agents (SYNeamicin D™ and SYNeamicin G™), ⍺-Microtubule (SYNtansine™) and β-Microtubule (SYNstatin E™ and SYNstatin F™) inhibitors as well as several unlaunched proprietary linker-payloads that were generated through the ongoing innovative efforts of the Synaffix R&D team..

毒素™ 是一个链接器有效负载平台，涵盖用于ADC产品开发的关键，经过验证的MOA。这包括强效拓扑异构酶1抑制剂（SYNtecan E™), DNA损伤剂（SYNeamicin D™ 和SYNeamicin G™), ⍺-微管（SYNtansine™) 微管（SYNstatin E™ 和合成抑素F™) 抑制剂以及通过Synpexure R＆D团队正在进行的创新努力产生的几个未AUNCHED专有链接器有效载荷。。

The combination of these three technologies provides developers with a 'one stop' and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.

这三种技术的结合为开发人员提供了一个“一站式”和易于使用的ADC技术平台，允许任何抗体开发者开发自己专有的ADC和任何ADC开发者进一步扩大其管道并提高其竞争地位。

About Lonza

关于Lonza

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence.

Lonza是制药，生物技术和营养市场的首选全球合作伙伴。我们通过支持客户提供有助于治疗各种疾病的新型创新药物，致力于创造更健康的世界。我们通过将技术洞察力与世界级制造，科学专业知识和卓越工艺相结合来实现这一目标。

Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry..

我们的业务旨在满足四个部门的客户复杂需求：生物制剂，小分子，细胞和基因以及胶囊和健康成分。 我们跨部门无与伦比的广泛产品使我们的客户能够将他们在医疗行业的发现和创新商业化。。

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 922 million in Half-Year 2023.

Lonza于1897年在瑞士阿尔卑斯山成立，目前在五大洲运营。我们拥有大约17500名全职员工，包括高绩效团队和个人人才，他们为我们自己的业务以及我们经营的社区做出了有意义的改变。该公司在2023年半年实现了31亿瑞士法郎的销售额，核心EBITDA为9.22亿瑞士法郎。

Find out more at www.lonza.com.

请访问www.lonza.com了解更多信息。

Follow @Lonza on LinkedIn Follow @LonzaGroup on Twitter

在LinkedIn上关注@Lonza在Twitter上关注@LonzaGroup

About SOTIO

关于索蒂奥

SOTIO Biotech (SOTIO) is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The SOTIO pipeline includes SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate which entered the clinic in 2022; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors as well as other molecules approaching clinical stage such as SOT201, our next-generation PD-1-inhibiting cytokine.

SOTIO Biotech（SOTIO）正在通过将引人注目的科学转化为患者利益来塑造癌症免疫疗法的未来。SOTIO管道包括SOT102，一种新一代Claudin-18.2靶向抗体-药物偶联物，于2022年进入临床；BOXR1030，一种代谢增强的CAR-T细胞疗法，靶向表达GPC3的肿瘤以及接近临床阶段的其他分子，如SOT201，我们的下一代PD-1抑制细胞因子。

SOTIO is a member of the PPF Group. For more information, please visit the company's website at www.sotio.com..

SOTIO是PPF组的成员。欲了解更多信息，请访问公司的网站www.sotio.com。。

SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries.

SOTIO是SOTIO Biotech a.s.在选定国家的注册商标。

SOURCE Synaffix

源语法